1. Summary of the Week
From June 13 to 19, a total of 20 agreements were signed worldwide. Within China’s biotech industry, there were four in-licensing deals and five domestic transactions.
In China, the largest deal involved Dimerix and Everest Medicines for the phase III asset repagermanium, with an upfront payment of $10 million and a total deal value of $340 million.
Globally, 11 deals were announced. The largest transaction was between JCR Pharmaceuticals and Acumen Pharmaceuticals to co-develop a novel blood-brain barrier-penetrating therapy for Alzheimer’s Disease, with a total deal value of $555 million.
2026年6月13日-19日，全球医药市场共签署了20项资产授权和合作协议。中国市场共达成9项交易，包括4项引进交易和5项国内交易。
国内市场上，本周最大的引进交易是云顶新耀与Dimerix就临床三期资产repagermanium达成独家商业化授权许可协议，首付款1000万美元，总金额可达3.4亿美元。
国际市场上，本周共签署了11项资产授权和合作协议。最大的交易是JCR Pharmaceuticals与Acumen Pharmaceuticals达成合作，共同开发针对阿尔茨海默病的增强型脑递送疗法，总金额可达5.55亿美元。
2. Licensing Deals
China Licensing and Cooperation Deals June 2026
| Deal Type | Licensor | Licensee | Assets | Disease | Stage | Total amount ($ million) |
Upfront ($ million) |
Deal Territory |
|---|---|---|---|---|---|---|---|---|
| China IL |
Dimerix | Everest Medicines 云顶新耀 |
repagermanium | focal segmental glomerulosclerosis (FSGS); COVID-19; diabetic nephropathy (DN) | Phase III | 340 | 10 | Chinese mainland; Hong Kong, Macao and Taiwan; Other |
| China IL |
Opterion Health | Shijiazhuang No.4 石家庄四药 |
OPT101 | chronic kidney disease (CKD); peritoneal dialysis | Phase I | Undisclosed | Undisclosed | Chinese mainland; Other |
| China IL |
Pfizer | Sinopharm Group 国药控股 |
fluconazole | oropharyngeal candidiasis; esophageal candidiasis; vulvovaginal candidiasis (VVC); cryptococcal meningitis; coccidioidomycosis; histoplasmosis; blastomycetic dermatitidis | Approved | Undisclosed | Undisclosed | Chinese mainland |
| China IL |
Ingenium Therapeutics | Refiorire Bio 睿芙细胞 |
gengleucel | acute myeloid leukaemia (AML) | Phase II | Undisclosed | Undisclosed | Chinese mainland; United States; Other |
| China Domestic |
Immunocan 伊米诺康 |
MabGalaxy 迈博智星 |
Bispecific/Multispecific Antibody Drugs | Undisclosed | Pre-Clinical | Undisclosed | Undisclosed | Global |
| China Domestic |
Biomap 百图生科 |
MegaStream | AI technology; Harbour Mice platform based AI antibody drugs | unknown/to be determined | Pre-Clinical | Undisclosed | Undisclosed | Global |
| China Domestic |
Harbour BioMed 和铂医药 |
MegaStream | fully human antibody platform; Harbour Mice platform based AI antibody drugs | unknown/to be determined | Undisclosed | Undisclosed | Undisclosed | Global |
| China Domestic |
Morning Gold Medicine 金辰医药 |
Kingworld Medicines 金活医药集团 |
modified gastrodia brain-health formula; zizhu leaf cleansing solution | insomnia; headache; dizziness; burn injury; pressure ulcers; diabetic foot | Pre-Clinical | Undisclosed | Undisclosed | Chinese mainland; Other |
| China Domestic |
Guangzhou University of Traditional Chinese Medicine 广州中医药大学 |
Morning Gold Medicine 金辰医药 |
zizhu leaf cleansing solution; modified gastrodia brain-health formula | burn injury; pressure ulcers; diabetic foot; insomnia; headache; dizziness | Pre-Clinical | Undisclosed | Undisclosed | Global |
2a. China Section
2b. Global Section
Global Licensing and Cooperation Deals June 2026
| Deal Type | Licensor | Licensee | Assets | Disease | Stage | Total amount ($ million) | Upfront ($ million) | Deal Territory |
|---|---|---|---|---|---|---|---|---|
| Collaboration | JCR Pharmaceuticals | Acumen Pharmaceuticals | sabirnetug | dementia in Alzheimer’s disease; mild cognitive impairment (MCI); Alzheimer’s disease (AD) | Phase II | 555 | Undisclosed | Global |
| Collaboration | Lilly TuneLab | Axcelead Drug Discovery Partners | AI-driven drug discovery and development | Undisclosed | Pre-Clinical | Undisclosed | Undisclosed | Global |
| Collaboration; License; Option | LabGenius | LG Chem | EVA antibodies | oncology | Pre-Clinical | Undisclosed | Undisclosed | Global |
| Collaboration | LG AI Research | D&D Pharmatech | oral peptide drug | unknown/to be determined | Pre-Clinical | Undisclosed | Undisclosed | Global |
| Collaboration | AbClon | GC Biopharma | in vivo CAR-T | oncology | Pre-Clinical | Undisclosed | Undisclosed | Global |
| Collaboration; License | Protillion Biosciences | Merck & Co. | multi-target drug discovery; Prot-MaP™ platform | Undisclosed | Pre-Clinical | Undisclosed | Undisclosed | Global |
| Collaboration | Oddifact | Mabion | rituximab biosimilar | diffuse large B-cell lymphoma (DLBCL); rheumatoid arthritis (RA) | Phase III | Undisclosed | Undisclosed | Global |
| License | Innoviva | Dr. Reddy’s Laboratories | durlobactam+sulbactam | infection; other bacterial infections; urinary tract infection (UTI); hospital-acquired bacterial pneumonia (HABP); postoperative infection; ventilator-associated bacterial pneumonia (VABP); Acinetobacter baumannii-calcoaceticus complex infection; acinetobacter baumannii infection | Approved | Undisclosed | Undisclosed | Other |
| License | King’s College London | AviadoBio | MiX™ RNAi gene silencing platform | Undisclosed | Undisclosed | Undisclosed | Undisclosed | Global |
| Collaboration | Porosome Therapeutics | CSIR | Drug Development and Collaboration | virus infection; Alzheimer’s disease (AD); disorder of nervous system; cystic fibrosis (CF); type 1 diabetes; type 2 diabetes; chronic obstructive pulmonary disease (COPD); lung cancer | Pre-Clinical | Undisclosed | Undisclosed | Global |
| License; Collaboration | Lonza | Antharis Therapeutics | dual-payload, site-specific ADC technology platform; dual-payload ADC program | cancer; gastrointestinal cancer | Undisclosed | Undisclosed | Undisclosed | Global |
Source: YAFO Life Sciences Research
3. M&A Deals
M&A Deals June 2026
| Status | Acquiree | Acquiror | Acquisition Type | Item | Total amount ($ million) | Upfront ($ million) |
|---|---|---|---|---|---|---|
| Proposed | RayThera | Biogen | Full Acquisition | Undisclosed | 1,000 | Undisclosed |
| Completed | 4E Therapeutics | Eli Lilly | Full Acquisition | 4ET1103 | Undisclosed | Undisclosed |
Source: YAFO Life Sciences Research
4. Top Deals of 2026
Top China Out-Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-01-30 | CSPC Pharma 石药集团 |
AstraZeneca | Endocrine & Metabolic | IND; Pre-Clinical | 18,500 | 1,200 |
| 2026-05-29 | Innovent Biologics 信达生物 |
Pfizer | Oncology | Pre-Clinical | 10,500 | 650 |
| 2026-01-13 | RemeGen 荣昌生物 |
AbbVie | Rare Disease; Oncology | Phase II | 5,600 | 650 |
| 2026-05-12 | Hengrui Pharmaceuticals 恒瑞医药 |
Bristol-Myers Squibb | Hematology; Oncology | Pre-Clinical | 15,200 | 600 |
| 2026-02-08 | Innovent Biologics 信达生物 |
Eli Lilly | Immunology; Oncology | Pre-Clinical | 8,850 | 350 |
| 2026-02-02 | Sanegene Bio 圣因生物 |
Genentech (Roche) | Unknown / To be determined | Pre-Clinical | 1,700 | 200 |
| 2026-01-12 | SciNeuro Pharma 赛神医药 |
Novartis | Neurology | Pre-Clinical | 1,665 | 165 |
| 2026-03-04 | CTTQ Pharma 正大天晴 |
Sanofi | Hematology; Rare Disease; Immunology; Oncology | Approved | 1,530 | 135 |
| 2026-03-29 | Insilico Medicine 英矽智能 |
Eli Lilly | Endocrine & Metabolic; Unknown / To be determined | Pre-Clinical | 2,750 | 115 |
| 2026-06-02 | Everest Medicines 云顶新耀 |
Travere Therapeutics | Neurology; Hematology; Rare Diseases; Immunology; Dermatology; Oncology; Genitourinary | Phase II | 1,142.5 | 112.5 |
Top China In-Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-05-14 | AriBio | Fosun Pharmaceutical 复星医药 |
Neurology; Cardiovascular; Genitourinary | Approved | Undisclosed | 80 |
| 2026-04-17 | Aligos Therapeutics | Amoytop Biotech 特宝生物 |
Infection; Gastroenterology | Phase II | 445 | 25 |
| 2026-03-09 | Rapport Therapeutics | Tenacia Biotechnology 元羿生物 |
Neurology; Psychiatry | Phase II | 328 | 20 |
| 2026-06-16 | Dimerix | Everest Medicines 云顶新耀 |
Infection; Genitourinary | Phase III | 340 | 10 |
Top China Domestic Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-05-29 | Genrix Bio 智翔金泰 |
YaoPharma 药友制药 |
Hematology; Rare Diseases; Immunology; Dermatology; Oncology | Filed | 253 | 42 |
| 2026-03-23 | Corxel Pharmaceuticals 箕星药业 |
Everest Medicines 云顶新耀 |
Cardiovascular | Approved | 50 | 30 |
| 2026-02-05 | Micot Technology 麦科奥特 |
Everest Medicines 云顶新耀 |
Genitourinary; Endocrine & Metabolic | Phase III | 172.48 | 27.82 |
| 2026-01-17 | Raynovent 众生药业 |
Qilu Pharmaceutical 齐鲁制药 |
Gastroenterology; Respiratory; Endocrine & Metabolic | Phase III | 139.10 | 27.82 |
| 2026-04-28 | Huahui Health 华辉安健 |
BeOne Medicines 百济神州 |
Oncology | Pre-Clinical | 2,024 | 20 |
| 2026-01-12 | Wan Bang De 万邦德 |
Hisoar Pharmaceutical 海翔药业 |
Neurology; Rare Disease | Pre-Clinical | 20.87 | 16.69 |
| 2026-01-06 | Accendatech 尚德药缘 |
Yifan Pharmaceutical 亿帆医药 |
Neurology; Ophthalmology; Respiratory; Hematology; Rare Disease; Immunology; Oncology | Phase III | 20.87 | 13.91 |
| 2026-02-04 | Akeso Biopharma; Kangrong Dongfang 康方生物 |
Jumpcan Pharmaceutical 济川药业 |
Rare Disease; Cardiovascular | Approved | 12.52 | 11.13 |
| 2026-01-20 | Insilico Medicine 英矽智能 |
Hengtai Biotechnology 衡泰生物 |
Neurology | Pre-Clinical | 66 | 10 |
| 2026-01-30 | PrimeGene 普祺医药 |
Jumpcan Pharmaceutical 济川药业 |
Rare Disease; Immunology; Dermatology; Otolaryngology | Phase III | 13.91 | 5.56 |
Top Global Licensing and Cooperation Deals 2026
| Date | Licensor | Licensee | Field | Stage | Total amount ($ million) |
Upfront ($ million) |
|---|---|---|---|---|---|---|
| 2026-03-20 | Synnovation Therapeutics | Novartis | Oncology | Phase I/II | 3,000 | 2,000 |
| 2026-06-01 | Edgewise Therapeutics | Servier | Musculoskeletal; Rare Diseases | Phase II | 2,650 | 1,550 |
| 2026-06-08 | Nurix Therapeutics | Roche | Haematology; Rare Diseases; Immunology; Oncology | Phase III | 2,300 | 700 |
| 2026-03-19 | Corium Therapeutics | Collegium Pharmaceutical | Psychiatry | Approved | 785 | 650 |
| 2026-03-09 | GSK | Alfasigma | Gastroenterology; Rare Disease; Dermatology; Endocrine & Metabolic | Filed | 690 | 300 |
| 2026-02-23 | Vir Biotechnology | Astellas Pharma | Oncology | Phase I/II | 1,705 | 240 |
| 2026-03-23 | Kali Therapeutics | Sanofi | Musculoskeletal; Immunology | Phase I | 1,230 | 180 |
| 2026-05-19 | Hansa Biopharma | Serb SA | Neurology; Rare Diseases; Musculoskeletal; Hematology; Immunology; Endocrinology & Metabolism | Approved | 130 | 124 |
| 2026-02-18 | CSL | Eli Lilly | Respiratory; Gastroenterology; Infection; Rare Disease; Musculoskeletal; Immunology; Cardiovascular; Oncology; Genitourinary; Endocrine & Metabolic | Phase III | Undisclosed | 100 |
| 2026-02-18 | Unnatural Products | Novartis | Cardiovascular | Pre-Clinical | 1,800 | 100 |
5. 2021-2025 China Innovative Drug Licensing Transactions
BioToChina.org 